EnsoData Raises $20M to Accelerate Commercialization of AI-powered Sleep Solutions

EnsoData, an innovator in AI healthtech solutions, announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its AI-powered sleep medicine solutions, improving the sleep care pathway for, in the US alone, an estimated 54 million patients suffering from sleep apnea.

“Traditional approaches in sleep medicine have left nearly 80% of patients undiagnosed and, of the 20% that are positively diagnosed, only 1 in 2 will be successfully treated,” stated Dr. Justin Mortara, Ph.D., President and CEO of EnsoData. “We need to expand patient access with simpler and more economic testing while embracing new approaches for sleep apnea therapies to improve this reality. EnsoData’s AI solutions are uniquely positioned to do both, and this Series B fundraise will allow us to rapidly scale our commercial team to deliver the next wave of AI-driven healthcare solutions.”

The EnsoData team is already growing, with the addition of a new Chief Commercial Officer, Bobby Cockrill, MBA, announced last month. “The appointment of Bobby is our first step toward establishing a substantial U.S. commercial team. His deep experience in diagnostics and managing strategic sales and sales operations are already having an exciting impact,” said Mortara.

“EnsoData has built a uniquely comprehensive platform that integrates disruptive, FDA-cleared clinical technologies across a complete care pathway,” stated Brian Butler, Partner at Questa Capital. “The team’s design discipline emphasizes usability and interoperability, an approach that has established EnsoData as a leader in sleep while positioning the company for future growth in adjacent specialties. We are thrilled to partner with such an experienced team at the helm of an innovative technology company.”

In addition to Questa Capital, existing investors participated in the Series B, including Zetta Venture Partners, Venture Investors Health Fund, Supermoon Capital, and Inspire Medical Systems.

For more information, visit www.ensodata.com.

Source: EnsoData